Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin
Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
You may also be interested in...
Certiorari review of a Federal Circuit decision invalidating Vascepa patents “is not warranted,” Hikma and Dr Reddy’s Laboratories have argued, claiming that the premise of originator Amarin’s petition to the US Supreme Court is “false.”
Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.
Hikma has won more time to respond to Amarin’s certiorari petition to the US Supreme Court over a Federal Circuit decision invalidating Vascepa intellectual property – but not the 45 days the company was looking for. Meanwhile, Amarin’s CEO John Thero is to stand down later this year.